Citations

Clear

554 citation(s) found for "Li, Gerald".

Disease understanding in patients newly diagnosed with atrial fibrillation
Kaufman, Brystana G. , Kim, Sunghee , Pieper, Karen S. , Ezekowitz, Michael D. , Mahaffey, Kenneth W. , Singer, Daniel E. , Ansell, Jack , Kowey, Peter R. , Rieffel, James A, Piccini, Jonathan P. , O’Brien, Emily C. , Allen, Larry A. , Gersh, Bernard J. , Naccarelli, Gerald V. , Fonarow, Gregg C. , Chan, Paul S. , Freeman, James V. , Peterson, Eric D.

Mayo Clinic

Heart | August 8, 2017 | Volume: 104 | Issue: 6 | Pages: 494-501

10.1136/heartjnl-2017-311800 | PMID 28790169 Get It

Objective To describe self-reported disease understanding for newly diagnosed patients with atrial fibrillation (AF) and assess (1) how disease understanding changes over the first 6 months after diagnosis and (2) the relationship between patient understanding of therapies at baseline and treatment receipt at 6 months among treatment-naïve patients. Methods We analysed survey data from SATELLITE (Survey of Patient Knowledge and Personal Priorities for Treatment), a substudy of patients with new-onset AF enrolled in the national Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT) II registry across 56 US sites. Patients were surveyed at the baseline and 6-month follow-up clinic visits using Likert scales. Results Among 1004 baseline survey responses, patients’ confidence in their understanding of rhythm control, ablation, anticoagulation and cardioversion was suboptimal, with ‘high’ understanding ranging from 8.5% for left atrial appendage closure to 71.3% for rhythm therapy. Of medical history and demographic factors, education level was the strongest predictor of reporting ‘high’ disease understanding. Among the 786 patients with 6-month survey data, significant increases in the proportion reporting high understanding were observed (p<0.05) only for warfarin and direct oral anticoagulants (DOACs). With the exception of ablation, high understanding for a given therapeutic option was not associated with increased use of that therapy at 6 months. Conclusions About half of patients with new-onset AF understood the benefits of oral anticoagulant at the time of diagnosis and understanding improved over the first 6 months. However, understanding of AF treatment remains suboptimal at 6 months. Our results suggest a need for ongoing patient education. Clinical trial registration Clinicaltrials.gov. Identifier: NCT01701817.
Yolk Sac Carcinoma: An Immunohistochemical and Clinicopathologic Review
Kramer, Stephen A., Wold, Lester E., Gilchrist, Gerald S., Svensson, Jan, Kelalis, Panayotis P.

Mayo Clinic

Journal of Urology | June 30, 2017 | Volume: 131 | Issue: 2 | Pages: 315-318

10.1016/s0022-5347(17)50361-4 | PMID 6199521 Get It

Intraoperative Irradiation: A New Technique in Pediatric Oncology
Kaufman, Bruce H., Gunderson, Leonard L., Evans, Richard G., Burgert, E. Omer, Gilchrist, Gerald S., Smithson, W. Anthony

Mayo Clinic

Journal of Urology | June 30, 2017 | Volume: 133 | Issue: 6 | Pages: 1135-1135

10.1016/s0022-5347(17)49426-2 Get It

The Etiology and Treatment of Delayed Bleeding Following Percutaneous Lithotripsy
Patterson, David E., Segura, Joseph W., LeRoy, Andrew J., Benson, Ralph C., May, Gerald R.

Mayo Clinic

Journal of Urology | June 30, 2017 | Volume: 133 | Issue: 3 | Pages: 447-451

10.1016/s0022-5347(17)49015-x | PMID 3973995 Get It

Percutaneous Lithotripsy
Segura, Joseph W., Patterson, David E., LeRoy, Andrew J., May, Gerald R., Smith, Lynwood H.

Mayo Clinic

Journal of Urology | June 30, 2017 | Volume: 130 | Issue: 6 | Pages: 1051-1054

10.1016/s0022-5347(17)51678-x | PMID 6644881 Get It

Embryonal Rhabdomyosarcoma of the Bladder and Prostate in Childhood
Timmons, John W., Burgert, E. Omer, Soule, Edward H., Gilchrist, Gerald S., Kelalis, Panayotis P.

Mayo Clinic

Journal of Urology | June 30, 2017 | Volume: 113 | Issue: 5 | Pages: 694-697

10.1016/s0022-5347(17)59555-5 | PMID 1127815 Get It

Percutaneous Removal of Kidney Stones: Review of 1,000 Cases
Segura, Joseph W., Patterson, D E, LeRoy, Andrew J., Williams, Hugh J., Benson, Ralph C., May, Gerald R., Bender, Claire E., Barrett, David M.

Mayo Clinic

Journal of Urology | June 29, 2017 | Volume: 134 | Issue: 6 | Pages: 1077-1081

10.1016/s0022-5347(17)47633-6 | PMID 4057395 Get It

CHECKMATE 647: A PHASE 2, OPEN‐LABEL STUDY OF NIVOLUMAB IN RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA OR RELAPSED/REFRACTORY PRIMARY TESTICULAR LYMPHOMA
Nayak, Lakshmi , Ferreri, Andrés J.M. , Batlevi, Connie Lee , Batchelor, Tracy T. , Rubenstein, James L. , Johnston, Patrick B. , Ramchandren, Radhakrishnan , Soussain, Carole , Becker, Kevin, Illerhaus, Gerald , Herrera, Alex F. , Masood, Aisha, IWAMOTO, FABIO MASSAITI , Santoro, Armando , Singer, Samuel , Drappatz, Jan , Witzens‐Harig, Mathias , Shipp, Margaret Ann

Mayo Clinic

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 420-421

10.1002/hon.2440_2 Get It

AAPM Medical Physics Practice Guideline 8.a.: Linear accelerator performance tests
Smith, Koren, Balter, Peter , Duhon, John, White, Gerald A., Vassy, David L., Miller, Robin A., Serago, Christopher F., Fairobent, Lynne

Mayo Clinic

Journal of Applied Clinical Medical Physics | May 26, 2017 | Volume: 18 | Issue: 4 | Pages: 23-39

10.1002/acm2.12080 | PMID 28548315 Get It

AbstractPurposeThe purpose of this guideline is to provide a list of critical performance tests in order to assist the Qualified Medical Physicist (QMP) in establishing and maintaining a safe and effective quality assurance (QA) program. The performance tests on a linear accelerator (linac) should be selected to fit the clinical patterns of use of the accelerator and care should be given to perform tests which are relevant to detecting errors related to the specific use of the accelerator.MethodsA risk assessment was performed on tests from current task group reports on linac QA to highlight those tests that are most effective at maintaining safety and quality for the patient. Recommendations are made on the acquisition of reference or baseline data, the establishment of machine isocenter on a routine basis, basing performance tests on clinical use of the linac, working with vendors to establish QA tests and performing tests after maintenance.ResultsThe recommended tests proposed in this guideline were chosen based on the results from the risk analysis and the consensus of the guideline's committee. The tests are grouped together by class of test (e.g., dosimetry, mechanical, etc.) and clinical parameter tested. Implementation notes are included for each test so that the QMP can understand the overall goal of each test.ConclusionThis guideline will assist the QMP in developing a comprehensive QA program for linacs in the external beam radiation therapy setting. The committee sought to prioritize tests by their implication on quality and patient safety. The QMP is ultimately responsible for implementing appropriate tests. In the spirit of the report from American Association of Physicists in Medicine Task Group 100, individual institutions are encouraged to analyze the risks involved in their own clinical practice and determine which performance tests are relevant in their own radiotherapy clinics.
Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation
Black‐Maier, Eric , Kim, Sunghee , Steinberg, Benjamin A. , Fonarow, Gregg C. , Kowey, Peter R. , Ansell, Jack , Mahaffey, Kenneth W. , Go, Alan S. , Piccini, Jonathan P. , Investigators, for the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT‐AF), Freeman, James V. , Gersh, Bernard J. , Naccarelli, Gerald V. , Hylek, Elaine M. , Peterson, Eric D. , Investigators, for the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT‐AF), Steinberg, Benjamin A

Mayo Clinic

Clinical Cardiology | May 23, 2017 | Volume: 40 | Issue: 9 | Pages: 746-751

10.1002/clc.22726 | PMID 28543401 Get It

BackgroundOral anticoagulation (OAC) therapy is associated with increased periprocedural risks after cardiac implantable electronic device (CIED) implantation. Patterns of anticoagulation management involving non–vitamin K antagonist oral anticoagulants (NOACs) have not been characterized.HypothesisAnticoagulation strategies and outcomes differ by anticoagulant type in patients undergoing CIED implantation.MethodsUsing the nationwide Outcomes Registry for Better Informed Treatment of Atrial Fibrillation, we assessed how atrial fibrillation (AF) patients undergoing CIED implantation were cared for and their subsequent outcomes. Outcomes were compared by oral anticoagulant therapy (none, warfarin, or NOAC) as well as by anticoagulation interruption status.ResultsAmong 9129 AF patients, 416 (5%) underwent CIED implantation during a median follow‐up of 30 months (interquartile range, 24–36). Of these, 60 (14%) had implantation on a NOAC. Relative to warfarin therapy, those on a NOAC were younger (70.5 years [range, 65–77.5 years] vs 77 years [range, 70–82 years]), had less valvular heart disease (15.0% vs 31.3%), higher creatinine clearance (67.3 [range, 59.7–99.0] vs 65.8 [range, 50.0–91.6]), were more likely to have persistent AF (26.7% vs 22.9%), and use concomitant aspirin (51.7% vs 35.2%). OAC therapy was commonly interrupted for CIED in 64% (n = 183 of 284) of warfarin patients and 65% (n = 39 of 60) of NOAC patients. Many interrupted patients received intravenous bridging anticoagulation: 33/183 (18%) interrupted warfarin and 4/39 (10%) interrupted NOAC patients. Thirty‐day periprocedure bleeding and stroke adverse events were infrequent.ConclusionsManagement of anticoagulation among AF patients undergoing CIED implantation is highly variable, with OAC being interrupted in more than half of both warfarin‐ and NOAC‐treated patients. Bleeding and stroke events were infrequent in both warfarin and NOAC‐treated patients.